Overview of Dr. Matous
Jeffrey Matous, MD, is a hematologist who focuses on the treatment of plasma cell diseases, especially clinical care and research for patients who have multiple myeloma, Waldenström Macroglobulinemia and amyloidosis. Dr. Matous is passionate about educating his patients about these diseases and is experienced in the field of blood and marrow transplantation as a treatment therapy.
Dr. Matous was born in Sarnia, Ontario, Canada and raised in Seattle, WA; he received his medical degree with honors from the University of Washington. Dr. Matous then completed his internal medicine residency and chief residency at the University of Colorado Health Sciences Center. His fellowship training in hematology and bone marrow transplantation was completed at the University of Washington and the Fred Hutchinson Cancer Research Center. He then returned to Denver to practice and has been with the CBCI team since 2010. In addition to his work with our patients and team, Dr. Matous is also a clinical professor of medicine at the University of Colorado, a member of the Sarah Cannon Research Institute Myeloma Executive Committee and serves on the International Waldenström Macroglobulinemia Working Group.
He has been recognized as an outstanding clinical teacher of the medicine house staff. Further, Dr. Matous is the lead investigator in clinical trials in the areas of Waldenstrom’s Macroglobulinemia, multiple myeloma, and amyloidosis, and has been recognized by his peers as a Top Doctor regularly for more than two decades.
Dr. Matous is married with three adult children. Outside of work he enjoys cycling, languages, and our nation’s pastime.
Office
1721 E 19th Ave
#300
Denver, CO 80218
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 1990 - 1994
- University of ColoradoResidency, Internal Medicine, 1985 - 1989
- University of Washington School of MedicineClass of 1985
Certifications & Licensure
- CO State Medical License 1988 - 2025
- MT State Medical License 2004 - 2025
- NE State Medical License 2003 - 2022
- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor Start of enrollment: 2004 Mar 01
- Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation Start of enrollment: 2005 Nov 01
- Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant Start of enrollment: 2007 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014.Nizar J Bahlis, Christy Samaras, Donna Reece, Michael Sebag, Jeffrey Matous
Clinical Lymphoma, Myeloma & Leukemia. 2024-12-01 - Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.Sosana Delimpasi, Meletios A Dimopoulos, Jan Straub, Argiris Symeonidis, Luděk Pour
American Journal of Hematology. 2024-09-01 - 2 citationsBiomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.Constantine S Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee
Blood Advances. 2024-04-09
Journal Articles
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s MacroglobulinemiaJeffrey V Matous, M Lia Palomba, Steven P Treon, The New England Journal of Medicine
Abstracts/Posters
- A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Ma...Jeffrey V. Matous, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Anthem PPO
BCBS Blue Card PPO
BCBS Illinois BlueChoice Select
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Coventry Health Care PPO PlatinumCoventry Missouri - HMO/POS
First Health PPO
Great West PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Kaiser Permanente
Multiplan PHCS PPO
Multiplan PPO
Rocky Mountain Group/Indiv - HMO/Private Pay
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: